Efficacy and safety of statin and fibrate combination therapy in lipid management
Abstract Adequate control of hyperlipidemia is of paramount importance for prevention of vascular events. Statins and fibrates are well established treatments for hyperlipidemia. Combination therapy with a statin and fibrate offers significant therapeutic advantage for the treatment of severe or ref...
Gespeichert in:
| Veröffentlicht in: | Diabetes & metabolic syndrome clinical research & reviews 2012-07, Vol.6 (3), p.173-174 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 174 |
|---|---|
| container_issue | 3 |
| container_start_page | 173 |
| container_title | Diabetes & metabolic syndrome clinical research & reviews |
| container_volume | 6 |
| creator | Kota, Sunil Kumar Meher, Lalit Kumar Rao, Epari Sanjeeva Jammula, Sruti Modi, Kirtikumar D |
| description | Abstract Adequate control of hyperlipidemia is of paramount importance for prevention of vascular events. Statins and fibrates are well established treatments for hyperlipidemia. Combination therapy with a statin and fibrate offers significant therapeutic advantage for the treatment of severe or refractory mixed hyperlipidemia. Although such a combination does increase the risk of myopathy, with an incidence of approximately 0.12%, this small risk of myopathy rarely outweighs the established morbidity and mortality benefits of achieving lipid goals. Nevertheless, a higher incidence of myopathy has been reported with statin monotherapy. Statin + fibrate therapy should be considered if monotherapy or adding other drugs (e.g. cholesterol absorption inhibitors, omega-3 fatty acids or nicotinic acid) did not achieve lipid targets or is impractical. The current article focuses on recent studies highlighting the beneficial effects of this combination. |
| doi_str_mv | 10.1016/j.dsx.2012.09.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1178668300</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1871402112001555</els_id><sourcerecordid>1178668300</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-f6cebf657c2e476021a4c8b8641d9572b0b5923ae3456c63ab59c8a529dda5ae3</originalsourceid><addsrcrecordid>eNp9kU-P1SAUxYnROH_0A7gxXbpp5UKhNCYmZjI6JpMYo64JhYvybOkTeMZ-e3nzRhcuXAEn59xcfoeQZ0A7oCBf7jqXf3WMAuvo2FE6PiDnoAbVUs77h3d3aHvK4Ixc5LyjVIiRjY_JGeMg1Kj4Ofl47X2wxm6Nia7JxmPZmtU3uZgS4p3ow5RMwcauyxRildfYlG-YzH5rqmUO--CaxUTzFReM5Ql55M2c8en9eUm-vL3-fHXT3n549_7qzW1r-x5K66XFyUsxWIb9IOuSprdqUrIHN4qBTXSqy3KDvBfSSm7q0yoj2OicEVW-JC9Oc_dp_XHAXPQSssV5NhHXQ9YAg5JScUqrFU5Wm9acE3q9T2ExadNA9ZGk3ulKUh9JajrqSrJmnt-PP0wLur-JP-iq4dXJgPWTPwMmnW3AaNGFhLZot4b_jn_9T9rOIdYm5u-4Yd6thxQrPQ0614z-dKzy2CQwSkEIwX8D7Q6Yzw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1178668300</pqid></control><display><type>article</type><title>Efficacy and safety of statin and fibrate combination therapy in lipid management</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kota, Sunil Kumar ; Meher, Lalit Kumar ; Rao, Epari Sanjeeva ; Jammula, Sruti ; Modi, Kirtikumar D</creator><creatorcontrib>Kota, Sunil Kumar ; Meher, Lalit Kumar ; Rao, Epari Sanjeeva ; Jammula, Sruti ; Modi, Kirtikumar D</creatorcontrib><description>Abstract Adequate control of hyperlipidemia is of paramount importance for prevention of vascular events. Statins and fibrates are well established treatments for hyperlipidemia. Combination therapy with a statin and fibrate offers significant therapeutic advantage for the treatment of severe or refractory mixed hyperlipidemia. Although such a combination does increase the risk of myopathy, with an incidence of approximately 0.12%, this small risk of myopathy rarely outweighs the established morbidity and mortality benefits of achieving lipid goals. Nevertheless, a higher incidence of myopathy has been reported with statin monotherapy. Statin + fibrate therapy should be considered if monotherapy or adding other drugs (e.g. cholesterol absorption inhibitors, omega-3 fatty acids or nicotinic acid) did not achieve lipid targets or is impractical. The current article focuses on recent studies highlighting the beneficial effects of this combination.</description><identifier>ISSN: 1871-4021</identifier><identifier>EISSN: 1878-0334</identifier><identifier>DOI: 10.1016/j.dsx.2012.09.009</identifier><identifier>PMID: 23158983</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Anticholesteremic Agents - pharmacology ; Atorvastatin Calcium ; Drug Therapy, Combination ; Endocrinology & Metabolism ; Female ; Fenofibrate - pharmacology ; Fibrates ; Heptanoic Acids - pharmacology ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Hyperlipidemia ; Hyperlipidemias - blood ; Hyperlipidemias - complications ; Hyperlipidemias - drug therapy ; Hypolipidemic Agents - pharmacology ; Male ; Muscular Diseases - blood ; Muscular Diseases - drug therapy ; Muscular Diseases - prevention & control ; Pyrroles - pharmacology ; Risk Assessment ; Statin ; Treatment Outcome</subject><ispartof>Diabetes & metabolic syndrome clinical research & reviews, 2012-07, Vol.6 (3), p.173-174</ispartof><rights>Diabetes India</rights><rights>2012 Diabetes India</rights><rights>Copyright © 2012 Diabetes India. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-f6cebf657c2e476021a4c8b8641d9572b0b5923ae3456c63ab59c8a529dda5ae3</citedby><cites>FETCH-LOGICAL-c441t-f6cebf657c2e476021a4c8b8641d9572b0b5923ae3456c63ab59c8a529dda5ae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1871402112001555$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23158983$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kota, Sunil Kumar</creatorcontrib><creatorcontrib>Meher, Lalit Kumar</creatorcontrib><creatorcontrib>Rao, Epari Sanjeeva</creatorcontrib><creatorcontrib>Jammula, Sruti</creatorcontrib><creatorcontrib>Modi, Kirtikumar D</creatorcontrib><title>Efficacy and safety of statin and fibrate combination therapy in lipid management</title><title>Diabetes & metabolic syndrome clinical research & reviews</title><addtitle>Diabetes Metab Syndr</addtitle><description>Abstract Adequate control of hyperlipidemia is of paramount importance for prevention of vascular events. Statins and fibrates are well established treatments for hyperlipidemia. Combination therapy with a statin and fibrate offers significant therapeutic advantage for the treatment of severe or refractory mixed hyperlipidemia. Although such a combination does increase the risk of myopathy, with an incidence of approximately 0.12%, this small risk of myopathy rarely outweighs the established morbidity and mortality benefits of achieving lipid goals. Nevertheless, a higher incidence of myopathy has been reported with statin monotherapy. Statin + fibrate therapy should be considered if monotherapy or adding other drugs (e.g. cholesterol absorption inhibitors, omega-3 fatty acids or nicotinic acid) did not achieve lipid targets or is impractical. The current article focuses on recent studies highlighting the beneficial effects of this combination.</description><subject>Anticholesteremic Agents - pharmacology</subject><subject>Atorvastatin Calcium</subject><subject>Drug Therapy, Combination</subject><subject>Endocrinology & Metabolism</subject><subject>Female</subject><subject>Fenofibrate - pharmacology</subject><subject>Fibrates</subject><subject>Heptanoic Acids - pharmacology</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Hyperlipidemia</subject><subject>Hyperlipidemias - blood</subject><subject>Hyperlipidemias - complications</subject><subject>Hyperlipidemias - drug therapy</subject><subject>Hypolipidemic Agents - pharmacology</subject><subject>Male</subject><subject>Muscular Diseases - blood</subject><subject>Muscular Diseases - drug therapy</subject><subject>Muscular Diseases - prevention & control</subject><subject>Pyrroles - pharmacology</subject><subject>Risk Assessment</subject><subject>Statin</subject><subject>Treatment Outcome</subject><issn>1871-4021</issn><issn>1878-0334</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU-P1SAUxYnROH_0A7gxXbpp5UKhNCYmZjI6JpMYo64JhYvybOkTeMZ-e3nzRhcuXAEn59xcfoeQZ0A7oCBf7jqXf3WMAuvo2FE6PiDnoAbVUs77h3d3aHvK4Ixc5LyjVIiRjY_JGeMg1Kj4Ofl47X2wxm6Nia7JxmPZmtU3uZgS4p3ow5RMwcauyxRildfYlG-YzH5rqmUO--CaxUTzFReM5Ql55M2c8en9eUm-vL3-fHXT3n549_7qzW1r-x5K66XFyUsxWIb9IOuSprdqUrIHN4qBTXSqy3KDvBfSSm7q0yoj2OicEVW-JC9Oc_dp_XHAXPQSssV5NhHXQ9YAg5JScUqrFU5Wm9acE3q9T2ExadNA9ZGk3ulKUh9JajrqSrJmnt-PP0wLur-JP-iq4dXJgPWTPwMmnW3AaNGFhLZot4b_jn_9T9rOIdYm5u-4Yd6thxQrPQ0614z-dKzy2CQwSkEIwX8D7Q6Yzw</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>Kota, Sunil Kumar</creator><creator>Meher, Lalit Kumar</creator><creator>Rao, Epari Sanjeeva</creator><creator>Jammula, Sruti</creator><creator>Modi, Kirtikumar D</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120701</creationdate><title>Efficacy and safety of statin and fibrate combination therapy in lipid management</title><author>Kota, Sunil Kumar ; Meher, Lalit Kumar ; Rao, Epari Sanjeeva ; Jammula, Sruti ; Modi, Kirtikumar D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-f6cebf657c2e476021a4c8b8641d9572b0b5923ae3456c63ab59c8a529dda5ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anticholesteremic Agents - pharmacology</topic><topic>Atorvastatin Calcium</topic><topic>Drug Therapy, Combination</topic><topic>Endocrinology & Metabolism</topic><topic>Female</topic><topic>Fenofibrate - pharmacology</topic><topic>Fibrates</topic><topic>Heptanoic Acids - pharmacology</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Hyperlipidemia</topic><topic>Hyperlipidemias - blood</topic><topic>Hyperlipidemias - complications</topic><topic>Hyperlipidemias - drug therapy</topic><topic>Hypolipidemic Agents - pharmacology</topic><topic>Male</topic><topic>Muscular Diseases - blood</topic><topic>Muscular Diseases - drug therapy</topic><topic>Muscular Diseases - prevention & control</topic><topic>Pyrroles - pharmacology</topic><topic>Risk Assessment</topic><topic>Statin</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kota, Sunil Kumar</creatorcontrib><creatorcontrib>Meher, Lalit Kumar</creatorcontrib><creatorcontrib>Rao, Epari Sanjeeva</creatorcontrib><creatorcontrib>Jammula, Sruti</creatorcontrib><creatorcontrib>Modi, Kirtikumar D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes & metabolic syndrome clinical research & reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kota, Sunil Kumar</au><au>Meher, Lalit Kumar</au><au>Rao, Epari Sanjeeva</au><au>Jammula, Sruti</au><au>Modi, Kirtikumar D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of statin and fibrate combination therapy in lipid management</atitle><jtitle>Diabetes & metabolic syndrome clinical research & reviews</jtitle><addtitle>Diabetes Metab Syndr</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>6</volume><issue>3</issue><spage>173</spage><epage>174</epage><pages>173-174</pages><issn>1871-4021</issn><eissn>1878-0334</eissn><abstract>Abstract Adequate control of hyperlipidemia is of paramount importance for prevention of vascular events. Statins and fibrates are well established treatments for hyperlipidemia. Combination therapy with a statin and fibrate offers significant therapeutic advantage for the treatment of severe or refractory mixed hyperlipidemia. Although such a combination does increase the risk of myopathy, with an incidence of approximately 0.12%, this small risk of myopathy rarely outweighs the established morbidity and mortality benefits of achieving lipid goals. Nevertheless, a higher incidence of myopathy has been reported with statin monotherapy. Statin + fibrate therapy should be considered if monotherapy or adding other drugs (e.g. cholesterol absorption inhibitors, omega-3 fatty acids or nicotinic acid) did not achieve lipid targets or is impractical. The current article focuses on recent studies highlighting the beneficial effects of this combination.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>23158983</pmid><doi>10.1016/j.dsx.2012.09.009</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1871-4021 |
| ispartof | Diabetes & metabolic syndrome clinical research & reviews, 2012-07, Vol.6 (3), p.173-174 |
| issn | 1871-4021 1878-0334 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1178668300 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Anticholesteremic Agents - pharmacology Atorvastatin Calcium Drug Therapy, Combination Endocrinology & Metabolism Female Fenofibrate - pharmacology Fibrates Heptanoic Acids - pharmacology Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Hyperlipidemia Hyperlipidemias - blood Hyperlipidemias - complications Hyperlipidemias - drug therapy Hypolipidemic Agents - pharmacology Male Muscular Diseases - blood Muscular Diseases - drug therapy Muscular Diseases - prevention & control Pyrroles - pharmacology Risk Assessment Statin Treatment Outcome |
| title | Efficacy and safety of statin and fibrate combination therapy in lipid management |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T12%3A10%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20statin%20and%20fibrate%20combination%20therapy%20in%20lipid%20management&rft.jtitle=Diabetes%20&%20metabolic%20syndrome%20clinical%20research%20&%20reviews&rft.au=Kota,%20Sunil%20Kumar&rft.date=2012-07-01&rft.volume=6&rft.issue=3&rft.spage=173&rft.epage=174&rft.pages=173-174&rft.issn=1871-4021&rft.eissn=1878-0334&rft_id=info:doi/10.1016/j.dsx.2012.09.009&rft_dat=%3Cproquest_cross%3E1178668300%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1178668300&rft_id=info:pmid/23158983&rft_els_id=1_s2_0_S1871402112001555&rfr_iscdi=true |